Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder and Borderline Personality Disorder (PTSD-BPD)
A Pilot Effectiveness Trial of Cognitive Processing Therapy Augmented With Suicide Risk Management for Individuals With Comorbid PTSD and BPD
2 other identifiers
interventional
33
1 country
1
Brief Summary
Posttraumatic Stress Disorder (PTSD) with co-occurring Borderline Personality Disorder (BPD) (i.e., PTSD-BPD) is common (as high as 58%), debilitating, costly, and limited treatment options available for this population. PTSD-BPD is associated with even greater functional impairment and higher healthcare burden than either disorder alone. There are surprisingly few treatments available for this clinical profile, despite its association with major negative health outcomes, cost, and morbidity. There is a pressing need to innovate treatments that can effectively and efficiently treat PTSD-BPD. The existing treatments used for PTSD-BPD are lengthy, laborious, resource-intensive, and require complete cessation of suicidal behaviors prior to treatment. Furthermore, no integrated treatment has been innovated to deliver the active ingredients to efficiently affect the mechanisms underpinning this comorbidity. The investigators propose to examine an adapted version of a first-line PTSD intervention, Cognitive Processing Therapy, augmented with a Suicide Risk Management, i.e., (CPT+SRM) as a brief (12 sessions) and more parsimonious treatment alternative that strategically targets shared mechanisms underpinning PTSD and BPD. The purpose of this pilot study is to 1) collect initial feasibility, acceptability, and safety data on this adapted treatment, 2) conduct a pilot randomized clinical trial evaluating the efficacy of CPT+SRM versus Treatment as Usual (TAU) + SRM, and 3) evaluate two targets (i.e, improvements in emotional intensity and cognitive dysfunction) as mechanisms leading to change in our primary outcomes. Both treatment conditions will be administered via telehealth. Potential benefits include reduction in participants' PTSD, BPD and other mental health symptoms. Additionally, this work could benefit the community by improving the treatment repertoire for PTSD-BPD. Potential risks include emotional distress, suicidality, and/or self-harm. Participants may experience discomfort and/or distress while discussing participants trauma(s) and mental health. These risks will be mitigated using a suicide risk management protocol which therapists in the assessment of risk and protective factors of suicide, followed by documentation for the decision-making around the management of risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 9, 2020
CompletedFirst Posted
Study publicly available on registry
January 18, 2020
CompletedStudy Start
First participant enrolled
October 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2025
CompletedJanuary 17, 2024
January 1, 2024
2.3 years
January 9, 2020
January 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
A 30-item clinician administered structured interview based on the DSM-5 PTSD criteria.
Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up
Borderline Symptom List 23 (BSL-23) [SELF-REPORT]
A self-report measure of borderline personality disorder (BPD) severity. The measure captures subjective ratings of the following symptoms: self-perception, affect regulation, self destruction, dysphoria, loneliness, intrusions, and hostility (Bohus et al., 2009).
Baseline, once a week while in treatment (for 6 weeks)
Secondary Outcomes (27)
Suicide Attempt Self-Injury Interview (SASII)
3-weeks, Post-treatment/6-weeks, 3-month follow-up
Difficulties in Emotion Regulation Scale (DERS) [SELF-REPORT]
Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up
Posttraumatic Cognitions Inventory (PTCI) [SELF-REPORT]
Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up
Beck's Depression Inventory-II (BDI-II) [SELF-REPORT]
Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up
State-Trait Anxiety Inventory, Trait Version (STAI-T)
Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up
- +22 more secondary outcomes
Study Arms (2)
CPT + SRM
EXPERIMENTALParticipants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.
TAU + SRM
EXPERIMENTALParticipants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.
Interventions
CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
Eligibility Criteria
You may qualify if:
- Aged 18-65 years
- Must reside in the Bay Area, CA
- Current DSM-5 diagnosis of PTSD and BPD
- Must be willing to be audio- or videorecorded for assessment and treatment sessions
You may not qualify if:
- Acute mania, acute psychosis, or intellectual disability
- Conditions requiring medical attention to a potentially life-threatening illness (e.g., severe anorexia nervosa)
- Severe impairments in written and aural comprehension
- EU individuals
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Palo Alto Universitylead
- Toronto Metropolitan Universitycollaborator
- York Universitycollaborator
- Stanford Universitycollaborator
- National Institute of Mental Health (NIMH)collaborator
Study Sites (1)
Palo Alto University
Palo Alto, California, 94304, United States
Related Publications (2)
Resick, P. A., Monson, C. M., & Chard, K. M. (2016). Cognitive processing therapy for PTSD: A comprehensive manual. New York, NY: Guilford Press.
BACKGROUNDStanley, B., & Brown, G. (2012). Safety planning intervention: A brief intervention to mitigate suicide risk. Cognitive and Behavioural Practice, 19(2), 256-264.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Janice R Kuo, PhD
Palo Alto University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 9, 2020
First Posted
January 18, 2020
Study Start
October 1, 2022
Primary Completion
December 31, 2024
Study Completion
January 31, 2025
Last Updated
January 17, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share